Newsfeeds - Spark Newswire

1 minute read

Reported Late Monday March 13, Innoviva Announces FDA Advisory Committee Meeting To Review Sulbactam-Durlobactam An Investigational Targeted Antibiotic On April 17, 2023

Today, 8:09 AM

Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration's (FDA)

INVA

31 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 8:09 AM

On Friday, 497 companies set new 52-week lows.

AADI

1 minute read

Goldman Sachs Maintains Neutral on Innoviva, Lowers Price Target to $13

By Benzinga Newsdesk

Today, 8:09 AM

Goldman Sachs analyst Chris Shibutani maintains Innoviva (NASDAQ:INVA) with a Neutral and lowers the price target from $15 to $13.

INVA

1 minute read

EF Hutton Reiterates Buy on Innoviva, Maintains $22.5 Price Target

By Benzinga Newsdesk

Today, 8:09 AM

EF Hutton analyst Constantine Davides reiterates Innoviva (NASDAQ:INVA) with a Buy and maintains $22.5 price target.

INVA

1 minute read

Innoviva Q3 EPS $2.80 Up From $0.90 YoY, Sales $67.26M Down From $97.86M YoY

By Bill Haddad

Today, 8:09 AM

Innoviva (NASDAQ:INVA) reported quarterly earnings of $2.80 per share. This is a 211.11 percent increase over earnings of $0.90 per share from the same period last year. The company reported $67.26 million in sales this

INVA

1 minute read

Morgan Stanley Maintains Underweight on Innoviva, Raises Price Target to $14

By Benzinga Newsdesk

Today, 8:09 AM

Morgan Stanley analyst Matthew Harrison maintains Innoviva (NASDAQ:INVA) with a Underweight and raises the price target from $13 to $14.

INVA

1 minute read

News

A Look Into Healthcare Sector Value Stocks

By Benzinga Insights

Today, 8:09 AM

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

CGEM